2026-07770NoticeWallet

NIH Dangles West Nile Virus-Busting Antibodies for Licensing Deals

Published Date: 4/22/2026

Notice

Summary

The National Institutes of Health is offering licenses for new human antibodies that can block West Nile virus, a mosquito-borne illness with no current vaccine or treatment. These antibodies could help protect or treat people at risk, especially older adults and those with weak immune systems. Companies interested in developing these therapies can apply now, with some foreign patent protections available to boost market reach.

Free Policy Watch

New rules are filed every week. Most people never see them.

Pick a topic. PRIA watches every federal rule and tells you when one hits your household.

Pick a topic to get started

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

NIH Licensing Opportunity for Companies

The NIH is offering a license (HHS Ref. E-021-2026-0) for seven fully human monoclonal antibodies against West Nile virus (AIS-196, AIS-204, AIS-259, AIS-260, AIS-261, AIS-262, AIS-265). A provisional patent (No. 63/991,485) was filed on February 26, 2026, and foreign patent applications on selected inventions may be available to extend market coverage. Companies or parties interested in commercial licensing or collaborative research can contact Brian Bailey at 240-669-5128 or [email protected].

Potential New Protection for Older Adults

Researchers identified seven fully human monoclonal antibodies that strongly block West Nile virus infection and showed protective effects in mouse studies; these could be developed to prevent or treat disease for people at higher risk, especially older adults and people with weakened immune systems. There is currently no approved human WNV vaccine or specific antiviral treatment, so these antibodies offer a new prevention or treatment path starting from pre-clinical development.

Antibodies Available for Diagnostics and Surveillance

The antibody sequences and production tools are available for licensing to produce high-quality reagents for West Nile virus testing, diagnosis, surveillance, and research. Public health laboratories and researchers could license these materials or collaborate with NIH to support WNV detection and monitoring.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
4/22/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
National Institutes of Health
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in